Carl Zeiss AG
Latest From Carl Zeiss AG
Swiss-based Vivior AG has developed a wearable Visual Behavior Monitor (VBM) designed to help surgical ophthalmologists determine the best treatment options for patients. The company's initial target is the $2.15bn global refractive and cataract surgery market.
Medtech M&A activity slowed in the last month of summer with just 16 mergers and acquisitions recorded on the Medtech Insight M&A Deal Tracker. However, the month included one billion-dollar deal and several deals in the ophthalmological sector.
OcuSciences Inc.'s OcuMet Beacon is a noninvasive and rapid diagnostic screening tool for retinal disease. The current ophthalmic standard of care, optical coherence tomography, evaluates structural change in retinal thickness or swelling after retinal damage has occurred, but OcuMet can provide a level of functional testing before damage occurs, which is especially important for latent diabetics or patients undiagnosed for retinal diseases.
A new intraocular lens being developed by LensGen Inc. essentially mimics the younger, natural human lens in curvature and flexibility so that cataract patients are able to physically accommodate over an entire range of vision from distance to near.
- Medical Devices
- Therapeutic Areas
- Carl Zeiss
- Western Europe
- Parent & Subsidiaries
- Carl Zeiss AG
- Senior Management
- Michael Kaschke, PhD, Pres. & CEO
- Contact Info
Carl Zeiss AG
Phone: (49) 7364 20 0
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.